Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study
用户1-TqkQKBj1O0
1个月前
41
10
已完结
1. 系统已在2025-10-16 09:31:53对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s40261-024-01410-x
文献链接: https://link.springer.com/10.1007/s40261-024-01410-x
其他信息:
出版社: Springer Science and Business Media LLC
作者: Michael Gerometta; Robert D. Henderson; Richard Friend; Leanne T. Cooper; Jing Zhao; Andrew W. Boyd; Perry F. Bartlett
全文下载地址: https://link.springer.com/content/pdf/10.1007/s40261-024-01410-x.pdf
